King Pharmaceuticals, Inc. (NYSE:KG)
| CAPS Rating |
|
|---|---|
| Open | $0.00 |
| Previous Close | $14.24 |
| Daily Range | $14.24 - $14.25 |
| 52-Week Range | $7.18 - $14.26 |
| Market Cap | $3.56B |
| P/E Ratio | 41.70 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 0 |
| Average Daily Volume | 0 |
KG
VS S&P 500 (SPY)
How do you think KG will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
KG Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
Related News and Articles
- Why Did My Stock Just Die? – The Motley Fool
- Merck Investors Can Sleep Easier (Not Easy) – The Motley Fool
- Is This Situation Special Enough? – The Motley Fool
- Investments for Income Lovers – The Motley Fool
- The Highest-Yielding Dow Stocks – The Motley Fool
- Dividend Stocks You Need to Watch Today – The Motley Fool
- 3 Stocks on Our Radar – The Motley Fool
- Curing Diseases Makes For a Bad Business Model – The Motley Fool
- This Just In: Upgrades and Downgrades – The Motley Fool
- Has Elan Become the Perfect Stock? – The Motley Fool
- 1 Cheap Biotech Small-Cap With Huge Potential – The Motley Fool
- The Disadvantage of a Successful Pipeline – The Motley Fool
- Side Effect of Low Side Effects: 20% Stock Gain – The Motley Fool
- This Drug Approval Is Good For the Industry – The Motley Fool
- Lipitor Loss? What's That? – The Motley Fool
- Kidney Cancer? There's a Drug for That – The Motley Fool
- FDA Approval Isn't Enough – The Motley Fool
- UPS Preps for Share Buybacks – The Motley Fool
- This Blockbuster Drug Just Got Better – The Motley Fool
- An Approval. Finally. – The Motley Fool
RSS Headlines
Fool UK
